Business Context and Reporting Period
Acrivon Therapeutics, Inc. (ACRV) is a clinical-stage biopharmaceutical company developing precision oncology medicines using its proprietary Generative Phosphoproteomics platform, AP3. The company focuses on identifying patients whose tumors are sensitive to specific treatments via its OncoSignature companion diagnostics. This filing covers the fiscal year ended December 31, 2024.
Key operational milestones in 2024 included:
- Advancement of lead candidate ACR-368 (prexasertib) in a registrational-intent Phase 2 trial for endometrial cancer, with positive interim data reported in September 2024.
- Initiation of the Phase 1 clinical trial for ACR-2316, an internally discovered dual WEE1/PKMYT1 inhibitor, in Q3 2024.
- Deprioritization of ovarian and bladder cancer programs for ACR-368 to focus resources on endometrial cancer and ACR-2316.
- Completion of a Private Investment in Public Equity (PIPE) transaction in April 2024, raising approximately $123.8 million in net proceeds.
Key Financial Metrics
The company has no revenue from product sales and continues to incur significant operating losses.
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(80,556) | $(60,388) |
| Research & Development Expenses | $63,992 | $46,024 |
| General & Administrative Expenses | $25,207 | $21,079 |
| Cash, Cash Equivalents, and Investments (Dec 31, 2024) | $184,600 | $127,458 |
| Accumulated Deficit (Dec 31, 2024) | $(196,976) | $(116,420) |
Liquidity: As of December 31, 2024, the company held $184.6 million in cash, cash equivalents, and investments. Management believes this is sufficient to fund operations into 2027.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by $20.2 million (33%) year-over-year, driven primarily by higher R&D spending.
- R&D Expense Growth: R&D expenses rose by $18.0 million. This was due to a $12.4 million increase in ACR-368 clinical trial costs (including $2.8 million in companion diagnostic milestones) and $3.4 million in costs for the new ACR-2316 program.
- Financing Activity: Net cash provided by financing activities was $121.0 million in 2024, compared to a net use of $1.6 million in 2023, largely due to the April 2024 PIPE transaction.
- Investing Activity: Net cash used in investing activities was $51.8 million in 2024, primarily due to the purchase of investments ($202.9 million) partially offset by maturities ($153.9 million).
Guidance, Outlook, and Risks
Outlook and Strategy:
- ACR-368: The company is prioritizing endometrial cancer. Interim data (Feb 2025) showed a 35% confirmed Objective Response Rate (ORR) in OncoSignature-positive patients, with 80% demonstrating tumor shrinkage. A confirmatory trial combining ACR-368 with anti-PD-1 is being planned.
- ACR-2316: Phase 1 dose escalation is ongoing. Initial clinical activity was observed in a patient at Dose Level 3. A clinical data update is anticipated in the second half of 2025.
- Capital Needs: While current cash reserves are projected to last into 2027, the company will require additional funding to support commercialization efforts if approvals are obtained.
Risks and Contingencies:
- Regulatory Approval: Success depends on obtaining FDA approval for ACR-368 and the co-development of the OncoSignature companion diagnostic with Akoya Biosciences.
- Profitability: The company expects to incur significant losses for the foreseeable future and may never achieve profitability.
- Third-Party Reliance: The company relies on third-party CROs for clinical trials and CMOs for manufacturing. Disruptions could delay development.
- Intellectual Property: The business depends on licensed IP from Eli Lilly and patents related to the AP3 platform.
Key Facts for Investor Verification
- Cash Runway: Verify the $184.6 million cash position and the projection to fund operations into 2027 against actual burn rates.
- Clinical Data Validation: Confirm the final analysis of the ACR-368 endometrial cancer Phase 2 trial, specifically the durability of response and the performance of the OncoSignature biomarker in the full cohort.
- ACR-2316 Progress: Monitor the safety profile and dose escalation results of the ACR-2316 Phase 1 trial, with an expected data update in H2 2025.
- Milestone Payments: Track the achievement of development milestones triggering payments to Eli Lilly (up to $168 million) and Akoya Biosciences (up to $20.3 million).
- Regulatory Status: Monitor the FDA's review of the Breakthrough Device designation for the ACR-368 OncoSignature assay and any potential accelerated approval pathways.